CIK 0000908259 · Non-accelerated filer<br>Smaller reporting company
Oncotelic Therapeutics, Inc.
Sign in to watch- Ticker
- OTLC
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 133679168
- Phone
- 650-635-7000
- Business address
- 29397 AGOURA RD., #107, AGUORA HILLS, CA, 91301
- Former names
- MATEON THERAPEUTICS INC, OXIGENE INC
- 4 Open-market buy CHAIRMAN AND CEO bought 126,888 shares at $0.03 ($4,327)
- 4 Open-market buy CHAIRMAN AND CEO bought 100,000 shares at $0.05 ($4,500)
- 4 Open-market buy CHAIRMAN AND CEO bought 120,000 shares at $0.05 ($6,000)
- 4 Open-market buy CHAIRMAN AND CEO bought 70,000 shares at $0.08 ($5,600)
- 4 Open-market buy CHAIRMAN AND CEO bought 20,000 shares at $0.07 ($1,360)
- 4 Open-market buy CHAIRMAN AND CEO bought 80,000 shares at $0.08 ($6,560)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Conversion CHIEF CLINICAL OFFICER acquired 938,646 shares (conversion)
- 4 Grant or award CHAIRMAN AND CEO acquired 259,302 shares (grant or award)
- 4 Conversion Director acquired 3,291,720 shares (conversion)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 298,837 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award CHIEF BUSINESS OFFICER acquired 102,519 shares (grant or award)
- 4 Open-market buy CHIEF FINANCIAL OFFICER bought 60,000 shares at an average $0.19 ($11,558)
- 4 Open-market buy CHIEF TECHNOLOGY OFFICER bought 22,173 shares at $0.18 ($4,098)
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 50,500 shares at $0.19 ($9,595)
- 3 Insider Initial Statement of Ownership
Page 2 of 17 · 325 filings